CliffBio
small molecule

NEBUPENT

PENTAMIDINE ISETHIONATE

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameNEBUPENT
Active ingredientPENTAMIDINE ISETHIONATE
Strength300MG/VIAL
Dosage formFOR SOLUTION
RouteINHALATION
ModalitySmall molecule
FDA approvalJune 1989
Marketing statusRX

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.